"Design of a drug delivery device for prioritization of cancer therapeutics"
Many cancer therapeutics fail to advance through phase II clinical trials due to cell-autonomous resistance of the patients. Our goal is to develop a novel device for local controlled drug delivery. The device would be used to assay individual patient's tumor cell response to locally-delivered therapies so that candidate therapies can be prioritized.
This approach minimizes the difficulties associated with systemic delivery and offers a unique potential for patient–based drug selection specially, when a library of new pharmaceutically active agents that are difficult to administer by conventional means, have to be examined.